Neurocrine Biosciences | NBIX - 贸易债权人



金融业
股票价格
USD
资产
USD 4.63B
现金及等价物
USD 713M
销售成本
USD 17.6M
流动资产
USD 2.52B
流动负债
USD 743.4M
债务
USD 428.4M
EBIT
USD 227.9M
EBITDA
USD 218.4M
员工
1.8K
EPS每股收益
USD 1.88
股本和储备
USD 3.25B
销售毛利
USD 787.9M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 12.75B
净收入
USD 209.5M
营业费用
USD 577.6M
营业利润
USD 227.9M
普通股股本
USD 100.1M
PE价格收益
835.47
税前利润
USD 239.4M
销售收入
USD 805.5M
销售和管理费用
USD 301.8M
股票
USD 69M
贸易债权人
USD 545.5M
应收帐款人
USD 686.8M


贸易债权人 更改 日
AbbVie USD 3.59B 28.65B 2025-12
Acadia Pharmaceuticals USD 10.9M 10.84M 2025-12
Agios Pharmaceuticals USD 13.75M 4.61M 2026-03
ALKERMES USD 107.95M 39.95M 2025-12
Alnylam Pharmaceuticals USD 115.72M 1.87M 2025-12
Amgen USD 20.89B 1.25B 2025-12
Biogen USD 358.5M 73.5M 2026-03
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Cytokinetics USD 105.62M 83.53M 2025-12
Enanta Pharmaceuticals USD 1.88M 63K 2025-12
Exelixis USD 29.62M 4.27M 2025-12
Gilead Sciences USD 715M 93M 2025-12
Halozyme Therapeutics USD 20.9M 5.54M 2025-12
Incyte USD 228.62M 1.41B 2026-03
Ionis Pharmaceuticals USD 26.03M 2.05M 2026-03
Nektar Therapeutics USD 10.77M 4.79M 2025-12
Neurocrine Biosciences USD 545.5M 425.6M 2025-12
Pfizer USD 5.02B 142M 2025-09
Prothena USD 5.88M 4.63M 2025-12
Regeneron Pharmaceuticals USD 1.03B 4.81B 2026-03
Repligen USD 30.01M 584K 2025-12
Rigel Pharmaceuticals USD 3.85M 3.44M 2025-09
Sarepta Therapeutics USD 280.84M 186.83M 2025-12
Teva Pharmaceutical Industries USD 2.6B 65M 2026-03
Ultragenyx Pharmaceutical USD 40.57M 6.33M 2025-09
Vertex Pharmaceuticals USD 3.43B 600.9M 2025-12
Xoma USD 2.65M 1.52M 2025-09